tbuckley/cabot-search huggingface dataset:
Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection
Authors: Jose R. Donado-Uña, Carolina Jiménez-Navarro, Marialving E. Fuentes-Salazar, Jose M. Ruiz-Giardin, Miguel A. Racionero-Casero, Victoria Valeri-Busto, Eva Prats-Graciá, Antonio Zapatero-Gaviria
Journal: European Respiratory Journal (2011)

Methods:  Retrospective review of patients with bronchiectasis with Pseudomonas aeruginosa (PA) isolated from sputum at least twice during the year prior to nebulized antibiotic (NA) onset and a minimum 6-month follow-up.   Results:  17 patients included (9 men), median age 69.7 yrs, average follow-up 753 days (183-1824). Nine patients received more than 1 NA during follow-up (31 NA courses in total): 16 colistin, 14 tobramycin, 1 gentamicin. Average treatment duration: 492.5 days (100-971).  Subjective improvement was referred by 12 patients (70.5%). Eradication of PA was achieved in 7 (41.2%), but 1 relapse occurred. 8 patients presented side effects at any time during NA (47%), mainly bronchospasm.  Table 1 shows a reduction in mean number of admissions/year and mean days of admission/year for all patients. A statistically significant reduction is observed when PA was eradicated.   Conclusions:  1. NA resulted in clinical improvement in 70.5% of cases and in eradication of PA in 41.2%. Side effects were observed in 47% of cases. 2. NA reduced number and days of admissions in all patients. A statistically significant reduction was observed if PA was erradicated in whom NA prevented nearly 2 admissions/year.
Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study
Authors: N. Altorki, M. Guarino, P. Lee, H. I. Pass, E. Filip, T. Bauer, D. Roychowdhury, T. Zaks, L. Ottesen, D. Yankelevitz
Journal: Journal of Clinical Oncology (2008)

7557 Background: Pazopanib is an oral angiogenesis inhibitor targeting VEGFR, PDGFR and c-kit. The present phase II open-label trial (NCT00367679; VEG105290) was designed to determine the clinical/biological activity and the safety of pazopanib given preoperatively in patients with stage I-II NSCLC. Methods: After initial biopsy and prior to scheduled surgery, eligible patients received pazopanib 800 mg QD for 2–6 weeks followed by a washout period of 7 days prior to surgery. The primary endpoint was tumor volume reduction assessed by high resolution CT (HRCT) images performed prior to and after pazopanib treatment. Secondary endpoints were response according to RECIST criteria and safety. The sequence of centrally reviewed scans was blinded. Analysis of surgical specimens as well as pre-and post-treatment plasma samples allowed comparative biological analyses to be performed. The target accrual was 33 patients between February 2007 and February 2008. Results: 26 patients were enrolled by November 30 2007, by which time 23 had pre and post treatment HRCT available. Median age was 65 yrs (51–79), 62% were female. Histologies were adenocarcinoma 62%, squamous cell 15%, and other NSCLC 23%. Stage IA: 16 patients; stage IB: 9 patients; stage IIA: 1 patient. Median duration of therapy was 18 days. Twenty pts (87%) had a reduction in tumor volume after pazopanib treatment. Tumor changes ranged from -86% to +17%. Three patients had a partial response. Grade 3 toxicities were seen in 3 patients: including ALT increase (2), hypertension (1), dyspnea (1), pneumonia (1), urinary tract infection (1), and lymphopenia (1). No grade 4 toxicities were seen. One patient discontinued due to Aes. Conclusions: Short-term pazopanib treatment demonstrated clear single-agent activity in early stage NSCLC with a favorable tolerability profile in this population. Further clinical development in this setting is planned. Final results will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline General Electric, Pneum Rx GlaxoSmithKline, Pneum Rx GlaxoSmithKline
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma: A randomized phase II trial
Authors: C. Hsu, A. Cheng, J. Shih, C. Yu, S. Kuo, C. Lin, T. Huang, P. Yang, C. Yang
Journal: Journal of Clinical Oncology (2007)

18072 Background: Epirubicin is active for treatment of non-small cell lung carcinoma (NSCLC) but its optimal dose was undetermined. This study was designed to evaluate the efficacy and safety of gemcitabine plus conventional-dose epirubicin for stage IIIB/IV NSCLC. Methods: Patients with histological or cytological diagnosis of stage IIIB/IV NSCLC who had not received prior chemotherapy were eligible. Patients were randomized to GE (gemcitabine, 1,000 mg/m 2 on days 1, 8, and 15 and epirubicin, 70 mg/m 2 on day 15) or GC (gemcitabine, 1,000 mg/m 2 on days 1, 8, and 15 and cisplatin, 80 mg/m 2 on day 15). Treatment cycles were repeated every 4 weeks. Objective tumor response and toxicity were evaluated by using the World Health Organization criteria. Results: No significant difference in baseline characteristics between patients randomized to GC (n=41) and GE (n=39) arms were found. The objective response rate was 31.0% (95% C.I. 16.4% to 45.5) for GC and 37.2.0% (95% C.I. 22.2% to 52.3%) for GE. The median time-to-treatment-failure and overall survival were 6.1 months (95% C.I. 4.9 to 7.4 months) and 13.2 months (95% C.I. 8.9 to 17.5 months) for GC and 6.2 months (95% C.I. 5.2 to 7.2 months) and 21.2 months (95% C.I. 14.6 to 27.8 months) for GE, respectively. More grade 3/4 neutropenia (71.8%) was noted in GE than in GC (43.9%). Febrile neutropenia was also more common in GE (4 patients) than in GC (1 patient). However, delay of protocol treatment due to leukopenia was similar between the 2 arms. Data on the expresssion of the excission repair cross-complimentation 1 (ERCC1), evaluated by immunohistochemical study for patients with available tumor tissue, will be presented. Conclusions: Gemcitabine plus conventional-dose epirubicin is an effective and well-tolerated regimen for patients with stage IIIB/IV NSCLC. No significant financial relationships to disclose.
Primary diffuse large B-cell colorectal lymphoma: One center experience in Peru
Authors: K. Portugal, B. E. Beltran, F. Hurtado de Mendoza, D. Morales, J. Malaga
Journal: Journal of Clinical Oncology (2008)

19532 Background: Primary colorectal lymphoma (PCL) is a very uncommon disease. Diffuse large B-cell lymphoma (DLBCL) PCL is the most frequent subtype and accounts less than 1% of colon malignancies Methods: The aim of this retrospective review was to describe the clinical characteristics and treatment outcomes of PCL. We retrospectively reviewed the records of PCL between 1997 and 2003 in one center in Peru. The statistical method was descriptive and survival was calculated using the Kaplan-Meier method. Results: From 1588 cases with Non Hodgkin Lymphoma, according Musshoff y Schmidt-Vollmer’s criteria twenty-three PCL (1.4%) were identified. Twenty-one were DLBCL, one T-cell lymphoma and one MALT lymphoma. Among the DLBCL PCL, the mean age at the time of presentation was 62 years and the male:female ratio was 1:2. Two patients had a previous history of ulcerative colitis. The most common symptoms were abdominal tumor (57.1%), abdominal pain (33.3%), diarrhoea (28,5%), bleeding (19%) and obstruction (14,3%). The most common endoscopic type was fungating mass (85,7%).The most frequent sites of involvement were: cecum (38,1%), ascending colon (33,3%) and rectum (23.8%); seven had stage I, 5 stage II and 9 stage III. Overall survival for staging was: 26, 11 and 10 months respectively. In early stage, 6 patients underwent hemicolectomy plus chemotherapy and 3 DLBCL patients received only chemotherapy with CHOP regimen. Two deaths were related to surgery and one death with sepsis before any treatment. Three patients are alive with 25, 59 and 91 months. In advanced disease, 9 patients received CHOP based chemotherapy and only one patient is alive after 17 months. Conclusions: Most PCL are DLBCL with frequent involvement of right colon and aggressive behaviour in Peru. No significant financial relationships to disclose.
구연 : 컨벤션홀 ; 라미부딘과 아데포비어에 치료 실패를 보이는 만성 B형간염 환자에서 엔테카비어 대체치료의 효능
Authors: 최원석, 고광철, 곽금연, 최문석, 이준혁, 백승운, 유병철
Journal: Clinical and Molecular Hepatology (2008)
An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites
Authors: D. L. Morton, N. Mozzillo, J. F. Thompson, M. C. Kelley, M. Faries, J. Wagner, S. Schneebaum, L. Schuchter, G. Gammon, R. Elashoff
Journal: Journal of Clinical Oncology (2007)

8508 Background: Active specific immunotherapy with BCG and an allogeneic, melanoma cell vaccine can induce antibody and T-lymphocyte immune responses to numerous antigens expressed by melanoma cells. This study compared overall and disease-free survival in patients receiving BCG plus placebo versus BCG plus MCV. Methods: Between June 1998 and November 2005, 1,656 patients without evidence of residual disease after resection of stage III (n = 1,160) or stage IV (n = 496) melanoma were randomly assigned to the two treatment arms (1:1). BCG was given as an immunologic adjuvant for the first two injections of both MCV and placebo, which thereafter were administered by intradermal injection every two weeks for the next three injections, every month for the remainder of the first year, every two months for the second year and every three months for years three, four and five. Results: Based on the recommendation of the independent Data and Safety Monitoring Board (DSMB), both studies were terminated after the interim analysis. The recommendation was based on a low probability of demonstrating significant improvement in survival of the BCG plus MCV arm if the study had continued to completion of follow-up and final analysis. Conclusions: This is the largest multicenter clinical trial of postoperative adjuvant immunotherapy after resection of melanoma metastatic to regional lymph nodes or distant sites. It is a landmark study not only because it represents the first randomized multicenter trial to use surgical resection as initial therapy for stage IV melanoma patients with up to five metastatic sites, but also because its results demonstrate excellent survival for the entire study population with 42.3% of stage IV and 63.4% of stage III patients projected to be alive at five years. Updated data for survival and immunologic endpoints which show a significant correlation between immune responses and survival will be provided at the meeting. [Table: see text]
Moving Beyond Cardio-Centricity in Heart Failure Risk Stratification
Authors: Barry A. Borlaug
Journal: Circulation (2015)

Heart failure (HF) remains the leading cause of hospitalization among older Americans.1 Survival is improving, and as such, the prevalence of HF is expected to increase 25% by the year 2030, leading to an annual healthcare cost of $70 billion. A number of cardiovascular problems have been identified that increase the risk for developing HF, including hypertension, coronary disease, obesity and diabetes.1 HF incidence can be reduced through lifestyle interventions that target these risk factors, with examples including maintenance of normal BMI, regular exercise, modest alcohol consumption, avoidance of smoking and consuming a healthy diet.2,3
Expression of phosphorylated epidermal growth factor receptor (p-EGFR) in early stage non-small cell lung cancer: its relationship with overexpression of EGFR and cyclooxygenase-2 (COX-2), and survival
Authors: S. J. Kim, Z. N. Rabbani, R. T. Vollmer, E. G. Schreiber, M. W. Dewhirst, Z. Vujaskovic, M. J. Kelley
Journal: Journal of Clinical Oncology (2005)

9614 Background: Epidermal growth factor receptor (EGFR) is widely overexpressed in various cancers, and reported to relate with growth and invasion of cancer cells. However, clinical significance of EGFR overexpression is still controversial because its correlation with prognosis is not universal. Thus, activated form of EGFR (phosphorylated EGFR, p-EGFR) may better predict prognosis. We determined the association of p-EGFR and prognosis, and its relationship with EGFR and COX-2, and other biomarkers. Methods: We immunohistochemically examined the expression of p-EGFR, EGFR, and COX-2 in 77 resected stage I/II non-small cell lung cancers (NSCLCs). Their correlation with prognosis and other biomarkers was also assessed including Ki-67, vascular endothelial growth factor (VEGF), and microvessel density (MVD). Results: EGFR overexpression, defined as membranous staining in more than 10% of cancer cells, was found in 37 patients (48.1%). 45 patients (58.4%) showed COX-2 overexpression, cytoplasmic granular staining in more than 10%. 28.6% of patients were positive expression of p-EGFR, cytoplasmic staining in more than 5% of cells (22/77). Expression of p-EGFR was significantly associated with COX-2 overexpression (p = 0.047), and showed a modest relationship with EGFR overexpression and high Ki-67 (p = 0.087, and 0.092, respectively). COX-2 overexpression also had a clear correlation with high Ki-67 expression (p = 0.011). However, no correlation was found between EGFR and COX-2 overexpression. VEGF expression and MVD showed no association with p-EGFR, EGFR, and COX-2 overexpression. Positive expression of p-EGFR was significantly related with a short disease free survival (p = 0.045), but not with overall survival. However, neither EGFR nor COX-2 overexpression were associated with prognosis (p > 0.05). Conclusions: Expression of p-EGFR may better predict increased malignant potential and worse prognosis of early stage NSCLC than EGFR overexpression itself and this may be related with COX-2 overexpression and high proliferative activity of cancer cells No significant financial relationships to disclose.
Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms.
Authors: V. Vaccaro, J. B. Fleming, R. A. Wolff, D. B. Evans, E. P. Tamm, C. H. Crane, M. M. Javle, J. L. Abbruzzese, J. E. Lee, G. R. Varadhachary
Journal: Journal of Clinical Oncology (2010)

4113 Background: There is no data on the value of surveillance CT scans in pts with resected pancreatic adenocarcinoma (PC). In practice, onset of symptoms and/or abnormal blood tests including rising CA 19-9 often provides a leading indicator of disease recurrence. Methods: We performed a retrospective review to assess the value of surveillance CT scans (every 4-6 mo) compared to clinical symptoms and CA 19-9 levels. We collected data on pts with PC who underwent potentially curative surgery from Feb 1998 to Dec 2008. Results: 476 pts underwent 479 surgeries (Whipple= 417, Total = 9, Distal = 53). Of these, 308 (65%) recurred (299 definite, 9 suspicious), 15 (3%) were lost to follow-up and 156 (33%) were without recurrence and alive at last follow-up (117, 25%) or died of other causes (39). Site of first recurrence was distant and/or regional in 269 (87%) and isolated local recurrence in 35 (11%). Ca19-9 and symptoms data on 296 pts is available. 161 pts were symptomatic, 147 in the 3 mo preceding their CT. In 65, symptoms were clearly related to their cancer recurrence and in 82, correlation was not definite; residual effects from surgery or adjuvant therapy may have contributed. Correlation between CA19-9, symptoms and survival in pts that recurred is shown in the Table. In 40 (15%), cancer recurrence was noted only on body CT scan in the absence of symptoms and/or elevation of CA19-9. In 37, CT scan showed distant and/or regional recurrence, and only 3 pts showed isolated local recurrence. CA 19-9 and symptoms appear to be additive prognostic factors - asymptomatic pts with a normal CA 19-9 had a MS of 18 mo (from recurrence) compared to 10mo for those with either CA 19-9 elevation or symptoms and 5 mo when both were observed (p<0.0001). Conclusions: These data suggest that in the majority of pts with resected PC, symptoms and/or CA19-9 elevation precedes or accompanies disease recurrence (85%). Additional analyses evaluating pt variables including neoadjuvant therapy, pathology, PS and response to treatment are underway. Median overall survival (OS) in months from time of recurrence (FR) and from time of surgery (FS) Symptoms+ Symptoms− Total No. Pts OS FR OS FS No. Pts OS FR OS FS Elevated CA 19.9 115 5 17 95 10 23 210 Normal CA 19.9 46 10 23 40 18 35 86 Total 161 135 296 No significant financial relationships to disclose.
Examining the Evidence for Using Synbiotics to Treat or Prevent Atopic Dermatitis
Authors: Mimi L. K. Tang, Caroline J. Lodge
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Early change in glucose metabolic rate (MRGlu) measured using FDG-PET in patients with high grade glioma (HGG) and correlation with response to temozolomide, and temozolomide + radiotherapy
Authors: N. G. Charnley, C. West, C. Barnett, C. S. Brock, G. M. Bydder, M. Glaser, E. S. Newlands, P. Price
Journal: Journal of Clinical Oncology (2005)

1532 Background: Temozolomide plus radiotherapy should now be the standard of care for patients with HGG (Stupp et al 2004; J Clin Oncol 22, 14S:2). We have previously shown that PET measurements of MRGlu can predict temozolomide response (Brock et al 2000; Br J Cancer 82:608–615). In this study, we compared the ability of PET to predict response to temozolomide vs temozolomide plus radiotherapy. Methods: 19 patients with HGG were studied. Patients with recurrent glioma received temozolomide 75mg/m2 daily for 7 weeks (n=8). Newly diagnosed patients received temozolomide 75mg/m2 daily plus radiotherapy 60Gy/30# over 6 weeks, followed by 6 cycles of adjuvant temozolamide (n=11). FDG PET scan and MRI were performed at baseline, and 7 and 19 weeks following initiation of treatment. Changes in MRGlu and MRI response were correlated with patient survival. Results: In patients receiving temozolomide alone, we confirmed our previous finding that early changes in MRGlu predicted response. Patients who survived >26 weeks vs ≤26 weeks showed a greater reduction in MRGlu measured at 7 weeks with median reductions of -34% and -4%, respectively (p=0.02). PET responders, defined as a reduction in MRGlu ≥25% (EORTC Guidelines 1999 Eur J Ca 35:1773–1782), had a longer survival than non-responders with mean survival times of 75 wks [95% CI 34–115] vs 20 wks [95% CI 14–26] (p=0.0067). In the small group of patients studied, there was no relationship between MRI response and survival (p=0.52). For patients receiving radiotherapy, there was no difference in survival between PET responders and non-responders (p=0.32). However, when PET response was measured 19 weeks following the initiation of treatment, there was a trend for increased survival in PET responders compared with non-responders (n=11, p=0.16). Conclusions: Early changes in MRGlu predict response to temozolomide, but not temozolomide plus radiotherapy. This may be due to the infiltration of tumours by glycolytic inflammatory cells following radiotherapy. FDG-PET assessment of radiotherapy response should be made later than for chemotherapy. No significant financial relationships to disclose.
Regional influenza A (H1N1) 2009 monovalent vaccination campaign - Skokie, Illinois, October 16-December 31, 2009.
Authors: C. Counard, A. Rigoni, J. Lockerby, A. Tennes, R. Czerwiniski, D. Prottsman, M. Slankard, A. le Tendre, B. Silverberg, P. Hanley, H. Mueller, B. Nowak, B. Gilley, M. Aleksic, M. DiFrancesca, C. Ballowe, B. Johnson, B. Jones, S. Reisberg, c. Braden, J. Hartford, B. Neirick, D. Codd, B. Kok, D. McLin, C. Starks
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
Coordinated Biochemical and Morphologic Examination of Hamster Tracheal Epithelium&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: David G. Kaufman, Mary S. Baker, Curtis C. Harris, Joseph M. Smith, Hollis Boren, Michael B. Sporn, Umberto Saffiotti
Journal: JNCI Journal of the National Cancer Institute (1972)

A respiratory epithelium of the hamster was examined by autoradiographic and biochemical techniques. Normal morphology was preserved in tracheas maintained in vitro for up to 3 hours. Biochemical analyses could be performed on epithelial cells obtained from the tracheal segments. Maintenance of isolated tracheal segments in vitro permitted Far greater incorporation of radioactively labeled precursors as compared to administration in vivo. 3H-5-uridine was incorporated into high molecular weight RNA in vitro and “maturation” of ribosomal RNA species occurred in vitro, as previously described for other cells and tissues. Biochemical events were correlated with cell type by concurrent quantitative autoradiography. Basal cells incorporated less 3H-5-uridine than mucous or ciliated cells. Correlated biochemical and morphologic study may be a means of evaluating biochemical changes in the presence of altered cell populations after carcinogen administration.